Trial reportBMC pediatrics2025
The prediction of phototherapy by early postnatal ETCOc in Chinese newborns.
Trial report in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Age-specific ETCOc measured by non-dispersive infrared spectroscopy predicts neonatal phototherapy.Pediatric research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundThe clinical significance of early postnatal ETCOc in the prediction of phototherapy (PT) for neonatal hyperbilirubinemia has not been fully characterized. We aimed to investigate the relationship between early postnatal ETCOc and the risk of PT within 7 days of life (7 DOLs) and diagnostic performance.
methodsThis is a secondary analysis of the infants randomized to the control group of the HEME trial. Cases were infants who had PT within 7 DOLs and controls were infants who did not require PT. Multivariate logistic regressions were used for the analyses of phototherapy and early postnatal ETCOc, adjusting for transcutaneous bilirubin level, gestational age, birth weight, sex and maternal blood types. We also evaluated the predictive performance of ETCOc by comparing multiple diagnostic parameters.
resultsIn 1,219 infants included, early postnatal ETCOc was associated with 2.98-(95% confidence interval [CI] = 2.22, 4.00, < 0.01), 2.53-(95%CI = 1.65, 3.90, < 0.01) and 2.42(95%CI = 1.05, 5.61, < 0.01)-fold increased odds of PT, respectively. Each one-unit increment of ETCOc was associated with earlier initiation, longer duration and more courses of PT. The ETCOc had a sensitivity of 65.4-87.5%, specificity of 71.7-75.8%, positive predictive values of 41.0-51.6%, and negative predictive values of 87.3-95.3%, with area under curves of 0.732-0.880 for the outcome of PT.
conclusionsA higher early postnatal ETCOc is linked with an increased risk of PT and PT characteristics within 7 DOLs. Early postnatal ETCOc can be a valuable indicator for predicting PT in early postnatal period.
trial registrationRegistration identifier ChiCTR2100051476 of the Chinese Clinical Trial Registry ( https://www.chictr.org.cn/ ).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.